All Drug Delivery articles – Page 9
-
NewsThe potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
-
ArticleChanging the paradigm of drug discovery processes with AI
We had the privilege of speaking to Cellarity’s CEO, Fabrice Chouraqui, about how the company is leveraging AI to completely revolutionise the drug discovery process and unlock treatments for a vast array of diseases, even in the absence of known targets.
-
NewsMini-colons offer improved cellular diversity, longevity and function
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
-
ArticleSmall molecules for regenerative medicine
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
-
NewsNew AI process for accurate enrolment of patients to clinical trial
The AI model screened the medical records of heart failure patients more accurately, quickly and cheaply, compared to study staff.
-
NewsCancer dependencies missed by some CRISPR guides
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
-
NewsEssential insights into HIV-1 latency mechanisms
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
-
NewsEpigenetic dysregulation mechanism in Crohn’s disease discovered
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
-
NewsMitigating fibrotic barriers in pancreatic cancer
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
-
ArticleeBook: Drop by drop: the future of liquid biopsy
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
-
News
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
-
ArticleThe promise of vectors targeting the LDL receptor
In this Q&A, Pascaline Lécorché, Head of Chemical Biology at Vect-Horus, outlines the potential of RNA interference therapeutics and the challenges of their use in vivo. There are several strategies to overcome these, and why peptide-based vectors targeting the LDL receptor are a promising approach.
-
ArticleWomen in Stem with Dr Rachel Lagiakos
Dr H. Rachel Lagiakos is a Senior Principal Scientist in the Therapeutics Group at Schrödinger which she joined in 2018. She completed her PhD in Synthetic Organic Chemistry at Monash University and began her medicinal chemistry career at Cancer Therapeutics (CTx) in Melbourne, Australia in 2012. At CTx, Rachel’s contributions ...
-
NewsTargeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
-
ArticleExploring the wonders of molecular biology
In this episode, we explore our understanding of DNA and its implications for health outcomes. Additionally, we discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods. Finally, we examine the evolving landscape of genetic technology and its potential impact on the ...
-
NewsNew method to predict effectiveness of MSCs for cartilage repair in vitro
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration.
-
ArticleHarnessing natural killer cells to combat age-related diseases
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
-
NewsFive HERV expression signatures linked to psychiatric disorders
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
-
ArticleEnhancing gene therapy with Circio
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy. ...